Navigation Links
BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
Date:1/30/2008

NOVATO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 19th Annual Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference in New York City on Wednesday, February 6, 2008 at 1:40 p.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... The latest ... Station (LSS), which prints and verifies labels automatically. Companies in the pharmaceutical and healthcare ... rate of up to 500 per minute. The Label Serialization Station can be fully ...
(Date:9/3/2015)... , Sept. 3, 2015  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced that Herbert Fritsche , ... ASPiRA LABS, is the recipient of the 2015 Abbott ... Biomarkers (ISOBM) for outstanding contributions to the field of ... award on October 5 th in Zakopane, ...
(Date:9/3/2015)... 2015 According to a new ... (HPLC, UHPLC, Flash), GC, Other Components (Autosamplers, Detectors, Fraction ... - Analysis & Global Forecasts to 2020", published by ... around 9.223 Billion by 2020 from USD 7.062 Billion ... Browse 141 tables and 36 figures spread through 277 ...
(Date:9/3/2015)... ... , ... If you plan to attend the 27th annual Tradeline College ... to sign up for the tour of Framingham State University's newest addition to Hemenway ... of the (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2
... 500th patient was supported with the,Berlin Heart EXCOR(R) Pediatric ... the first implantation of the device in 1990. The,patient, ... Memorial,Hospital in Chicago and has been successfully transplanted in ... been diagnosed a few weeks after birth with left,ventricular ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
... Quest Diagnostics scientists will present results of three ... diagnosis and treatment of chronic myeloid leukemia (CML) and ... American Society of Clinical Oncology (ASCO), scheduled for May ... Incorporated (NYSE: DGX ) is the world,s ...
Cached Biology Technology:500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 3Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 4Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 5
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... mixing it with sugar, making thick jams that last ... Institute of Standards and Technology (NIST) have discovered* a ... the life of many things including vaccines, food and ... addition to jams, sugars are often used to preserve ...
... unlucky encounter with a crab,s pinchers, consider that the ... times harder than acrylic glass and extremely fracture resistant, ... the U.S. West Coast may have had close encounters ... in a paper published online in advance of regular ...
... not just the climate that is struggling with what humans ... the pressure as well, according to Professor Greg Gibson,s recently ... a Clash Between Our Genes and Modern Life Is Making ... Sciences, suggests the increased rates of diseases such as diabetes, ...
Cached Biology News:Probing and controlling 'molecular rattling' may mean better preservatives 2Crab claws pack strengthening bromide-rich biomaterial 2'It takes a genome: How a clash between our genes and modern life is making us sick' 2
DTT 50 l...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: